Co-Authors
This is a "connection" page, showing publications co-authored by Blaine Mooers and Jie Wu.
Connection Strength
1.031
-
The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib. NPJ Precis Oncol. 2021 Jun 07; 5(1):48.
Score: 0.186
-
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. Ann Oncol. 2021 06; 32(6):817-819.
Score: 0.182
-
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol. 2021 02; 32(2):261-268.
Score: 0.178
-
RET kinase alterations in targeted cancer therapy. Cancer Drug Resist. 2020; 3(3):472-481.
Score: 0.172
-
Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib. J Biol Chem. 2019 07 05; 294(27):10428-10437.
Score: 0.161
-
Drug resistance profiles of mutations in the RET kinase domain. Br J Pharmacol. 2018 09; 175(17):3504-3515.
Score: 0.152